DarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes.
New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring for both clinical and self-reported impact.
Over three months, participants tracked blood glucose levels in the Dario app and worked with a live certified diabetes care and education specialist (CDCES). The results demonstrated clinically significant improvements in lab test results, platform-based data, and self-reported data, DarioHealth said.
Data published in the letter included a 2% reduction in average HbA1c lab values for participants, a significant reduction in fasting blood glucose (18%) and body mass index (10%), while glucose variability experienced a statistically significant improvement, as did the self-reported evaluation in weight and glucose control satisfaction.
“This clinical study re-confirms the persistent and substantial estimated HbA1c reductions we see in our other studies by demonstrating actual HbA1c reductions,” DarioHealth CMO Dr. Omar Manejwala said in the release. “The present study, while small, demonstrated a robust 2.0% reduction in measured HbA1c along with reductions in glucose variability.”
“These findings add valuable data to the little-understood application of digital self-monitoring and coaching in diabetes management,” added DarioHealth scientific & clinical director Yifat Hershcovitz. “Our findings provide clinical validation for digital self-monitoring to deliver personalized care alongside access to a live coach. The study demonstrates our data-driven technology is working for people with type 2 diabetes, guiding them in making effective decisions in diabetes management.”
